Literature DB >> 12525251

Transforming growth factor beta1 inhibits aldosterone and cortisol production in the human adrenocortical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression.

P Liakos1, D Lenz, R Bernhardt, J-J Feige, G Defaye.   

Abstract

Transforming growth factor beta1 (TGFbeta1) has been shown to exert strong inhibitory effects on adrenocortical cell steroidogenesis. However, the molecular targets of TGFbeta1 in adrenocortical cells appear to differ between species. Here, we report the first characterization of the regulatory effects of TGFbeta1 on the steroidogenic functions of the human adrenocortical tumor cell line NCI-H295R. After treatment with 2 ng/ml TGFbeta1 for 24 h, basal production of corticosterone, cortisol and androstenedione was dramatically decreased. When TGFbeta1 was added simultaneously with forskolin, the production of cortisol and 11-hydroxyandrostenedione was decreased by 85% whereas that of deoxycortisol was increased. When TGFbeta1 was added simultaneously with angiotensin II, aldosterone production was reduced by 80%. We observed that TGFbeta1 strongly inhibits forskolin-induced steroid 11beta-hydroxylase activity and CYP11B1 mRNA levels, as well as angiotensin II-induced aldosterone synthase activity and CYP11B2 mRNA levels. CYP11B1 and CYP11B2 gene products thus appear as the major steroidogenic enzymes down-regulated by TGFbeta1 in the human adrenocortical tumor cell line NCI-H295R.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525251     DOI: 10.1677/joe.0.1760069

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  13 in total

Review 1.  Transforming growth factor beta1 and aldosterone.

Authors:  Kota Matsuki; Catherine K Hathaway; Albert S Chang; Oliver Smithies; Masao Kakoki
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-03       Impact factor: 2.894

2.  Myeloid cells are capable of synthesizing aldosterone to exacerbate damage in muscular dystrophy.

Authors:  Jessica A Chadwick; Sarah A Swager; Jeovanna Lowe; Steven S Welc; James G Tidball; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Jill A Rafael-Fortney
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

Review 3.  Transforming growth factor-β1 and diabetic nephropathy.

Authors:  Albert S Chang; Catherine K Hathaway; Oliver Smithies; Masao Kakoki
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-30

Review 4.  The role of transforming growth factor β1 in the regulation of blood pressure.

Authors:  Kota Matsuki; Catherine K Hathaway; Marlon G Lawrence; Oliver Smithies; Masao Kakoki
Journal:  Curr Hypertens Rev       Date:  2014

5.  Estrogen receptor-alpha mediates an intraovarian negative feedback loop on thecal cell steroidogenesis via modulation of Cyp17a1 (cytochrome P450, steroid 17alpha-hydroxylase/17,20 lyase) expression.

Authors:  Fuminori Taniguchi; John F Couse; Karina F Rodriguez; Judith M A Emmen; Donald Poirier; Kenneth S Korach
Journal:  FASEB J       Date:  2006-12-08       Impact factor: 5.191

Review 6.  Lessons from the gene expression pattern of the rat zona glomerulosa.

Authors:  Koshiro Nishimoto; William E Rainey; Wendy B Bollag; Tsugio Seki
Journal:  Mol Cell Endocrinol       Date:  2012-12-31       Impact factor: 4.102

7.  SMAD3 inhibits SF-1-dependent activation of the CYP17 promoter in H295R cells.

Authors:  Natalia Derebecka-Holysz; Tomasz P Lehmann; Marcin Holysz; Wieslaw H Trzeciak
Journal:  Mol Cell Biochem       Date:  2007-09-05       Impact factor: 3.396

8.  Primary aldosteronism and impaired natriuresis in mice underexpressing TGFβ1.

Authors:  Masao Kakoki; Oleh M Pochynyuk; Catherine M Hathaway; Hirofumi Tomita; John R Hagaman; Hyung-Suk Kim; Oleg L Zaika; Mykola Mamenko; Yukako Kayashima; Kota Matsuki; Sylvia Hiller; Feng Li; Longquan Xu; Ruriko Grant; Alejandro M Bertorello; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-15       Impact factor: 11.205

Review 9.  TGF-β Physiology as a Novel Therapeutic Target Regarding Autoimmune Thyroid Diseases: Where Do We Stand and What to Expect.

Authors:  Efstratios Kardalas; Spyridoula Maraka; Maria Papagianni; George Paltoglou; Charalampos Siristatidis; George Mastorakos
Journal:  Medicina (Kaunas)       Date:  2021-06-14       Impact factor: 2.430

10.  Knockdown of SF-1 and RNF31 affects components of steroidogenesis, TGFβ, and Wnt/β-catenin signaling in adrenocortical carcinoma cells.

Authors:  Anna Ehrlund; Philip Jonsson; Lise-Lotte Vedin; Cecilia Williams; Jan-Åke Gustafsson; Eckardt Treuter
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.